Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015433 | 0.88 | NPSR1 (0.49) | NPSR1HPGDMTNR1AMTNR1BKMT2A | |
| SCHEMBL16015422 | 0.83 | NPSR1 (0.46) | NPSR1MTNR1AMTNR1BKCNH2 | |
| SCHEMBL14233697 | 0.83 | NPSR1 (0.50) | NPSR1HPGDMTNR1AMTNR1BKMT2A | |
| SCHEMBL14234497 | 0.77 | NPSR1 (0.44) | NPSR1HPGDMTNR1AMTNR1BGAA | |
| SCHEMBL10118215 | 0.76 | KDM4E (0.47) | NPSR1HPGDKMT2ATSHRKCNH2 | |
| SCHEMBL20109297 | 0.76 | NPSR1 (0.46) | NPSR1HPGDMTNR1AMTNR1BKMT2A | |
| SCHEMBL23015742 | 0.76 | PARP1 (0.47) | NPSR1MTNR1AKCNH2ALDH1A1 | |
| SCHEMBL22098490 | 0.74 | HPGD (0.57) | HPGDMTNR1AMTNR1BGAAKMT2A | |
| SCHEMBL14234496 | 0.74 | NPSR1 (0.44) | NPSR1HPGDMTNR1AMTNR1BGAA | |
| SCHEMBL10082882 | 0.73 | CHRNB2 (0.52) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343276-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343276-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | NPSR1 3125/4885HPGD 2161/4885MTNR1A 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.